SpringWorks Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference
To access the live webcast, please visit the Events & Presentations page within the Investors & Media section of the company’s website at https://ir.springworkstx.com. A replay of the webcast will be available on SpringWorks’ website for a limited time following the conference.
SpringWorks Therapeutics to Participate in the Jefferies London Healthcare Conference
STAMFORD, Conn., Nov. 12, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference,
Capsida Biotherapeutics to Present at 7th Annual Evercore HealthCONx Conference
Capsida Biotherapeutics ("Capsida"), a leading fully integrated next-generation gene therapy company developing treatments for rare and common diseases across all ages, today announced that the company will present at the 7(th) Annual Evercore HealthCONx Conference being held December 3-5,
Massachusetts Financial Services Co. MA lifted its holdings in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Free Report) by 20.2% during the 3rd quarter, Holdings Channel reports. The ...
J.P. Morgan said its top biotech picks for 2025 were Vertex (NASDAQ:VRTX), Travere (NASDAQ:TVTX), SpringWorks (NASDAQ:SWTX), ...
Key stocks to watch include Tarsus Pharmaceuticals and SpringWorks Therapeutics, both showing strong potential based on ...
3d
Mutual of America Capital Management LLC trimmed its position in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Free ...
In this article, we are going to take a look at where SpringWorks Therapeutics Inc. (NASDAQ:SWTX) stands against the other NASDAQ stocks. Potomac Wealth Advisors president Mark Avallone joined ...
All told, 7% of patients treated with SpringWorks' therapy had a complete response to treatment, and 95% of side effects liked to the drug were mild (grade 1 or 2), most commonly diarrhoea, rash ...
When we last visited SpringWorks, the company was trying to get its primary drug candidate nirogacestat through the FDA approval process. Nirogacestat is an oral small-molecule gamma-secretase ...
SpringWorks Therapeutics, Inc. SWTX incurred a loss of 72 cents per share in the third quarter of 2024, which was narrower than the Zacks Consensus Estimate of a loss of 76 cents. The company had ...
SpringWorks is the brainchild of Lara Sullivan, a former Pfizer R&D strategy executive who gained Pfizer's blessing to set up the firm with four lower-priority assets from the company's pipeline.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback